Effective from June 17th, the new manufacturing facility for CE-IVD & FDA approved assays premises will be fully operative. The new location is inside “Piero della Francesca” business center in downtown Turin and boasts a 2200 sqm surface for offices and labs, fully renovated. “We take a great amount of pride in the fact that we are able to invest in our Company at a time when many of the players in our market are continuing to cut back”, said Pierre Debiais, ELITechGroup CEO in a statement.
PSS and ELITech Group enter into a Joint Development, Distribution and Supply Agreement on PSS’s “geneLEAD”, a fully automated, sample-to-result, Real-Time PCR analyzer.
We are proud to announce that we are changing the company name of our French Manufacturing Unit from SEPPIM to ELITech Clinical Systems SAS (France) starting on January 10th, 2013.
Paris, January 2, 2013 – ELITech Group (“ELITech”) announces today the acquisition of 100% of the share capital of Vital Diagnostics Holding Corp. (“Vital Diagnostics”) from New River Management IV, LP and Third Security Staff 2001, LLC, both affiliates of Third Security, LLC, a US-based venture capital firm, and TeeTwo Nominees Pty Ltd.
On October 28, ELITech will present an informative and educational seminar on the "Clinical Impact of High Value Molecular Diagnostics." TriMark Publications hosts this timely forum on Molecular Diagnostics, bringing together industry leaders, thought leaders from university and hospital labs, influential decision makers, and laboratory directors to discuss the emergence of molecular diagnostic science.